<DOC>
	<DOCNO>NCT00861419</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics AMG 386 use combination AMG 706 , bevacizumab , sorafenib , sunitinib least one dose level combination safe well tolerate . AMG 386 man-made medication design stop development blood vessel cancer tissue . Cancer tissue rely development new blood vessel , process call angiogenesis , obtain supply oxygen nutrient grow .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability Pharmacokinetics AMG 386 When Used Combination With AMG 706 , Bevacizumab , Sorafenib , Sunitinib .</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Men woman least 18 year old . Subjects must pathologically document , definitively diagnose , advance solid tumor refractory standard treatment , standard therapy available , subject refuse standard therapy . Subjects enrol arm E &amp; F G &amp; H must pathologically document definitively diagnose advanced renal cell carcinoma . Measurable disease evaluable ( nonmeasurable ) disease per Response Evaluation Criteria Solid Tumors ( RECIST ) guideline . Eastern Cooperative Oncology Group ( ECOG ) performance status 2 . Subjects must able selfadminister AMG 706 ( arm B D ) sorafenib ( arm E F ) empty stomach ( fast 1 hour 1 hour postdose ) daily AMG 706 twice daily sorafenib . Subjects enrol arm G H must able selfadminister sunitinib daily . History lymphoma leukemia . Symptomatic untreated central nervous system metastases require concurrent treatment , inclusive limited surgery , radiation , corticosteroid . Subjects head neck cancer . Subjects lung squamous cell tumor large central ( locate adjacent within hilum mediastinum ) tumor lesion ≥ 3 centimeter , regardless histology For arm A C : Subjects ovarian cancer . History arterial venous thrombosis pulmonary embolism within 1 year enrollment ; history bleeding diathesis . Cardiovascular event within 1 year enrollment , myocardial infarction , unstable/severe angina , coronary/peripheral artery bypass graft , unstable cardiac arrhythmia require medication , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , cerebrovascular accident transient ischemic attack . For arm G H : LVEF ≤ 45 % , heart rate &lt; 50 / min . Chronic uncontrolled hypertension [ diastolic &gt; 85 mmHg ; systolic &gt; 145 mmHg ] . History pulmonary hemorrhage gross hemoptysis within 6 month enrollment . History significant GI surgery disease , would impair absorption . Unresolved toxicity prior anticancer therapy , define resolved Common Terminology Criteria Adverse Events ( CTCAE ) grade 0 1 , level dictate inclusion/exclusion criterion exception alopecia . Active infection within 2 week enrollment . Subject know tested positive HIV . Subject know chronic hepatitis ( e.g. , hepatitis B hepatitis C ) . Coumarin anticoagulant include warfarin , dose great 2 mg/day . The concurrent use low molecular weight heparin low dose warfarin ( ie , ≤ 2 mg daily prophylaxis central venous catheter thrombosis acceptable . Treatment anticancer therapy within 30 day study day 1 ( treatment bevacizumab within 42 day study day 1 ) unless prior write approval receive sponsor Hormonal antitumor therapy within 30 day enrollment . Does include hormone noncancer related condition ( eg , insulin diabetes , HRT ) use gonadotropinreleasing hormone ( GnRH ) agonists prostate cancer Therapeutic palliative radiation therapy within 2 week enrollment Prior treatment AMG 386 Prior radiation therapy abdomen For arm A , B , C , D : prior treatment bevacizumab , sorafenib , sunitinib , investigational agent know directly inhibit function vascular endothelial growth factor , vascular endothelial growth factor receptor , angiopoietins , angiopoietin receptor , unless prior write approval receive sponsor For arm E F : prior treatment sorafenib , unless prior write approval receive sponsor For arm G H : prior treatment sunitinib , unless prior write approval receive sponsor For arm E &amp; F G &amp; H : treatment bevacizumab within 42 day study day 1 , unless prior write approval receive sponsor Major surgery within 30 day enrollment recover prior surgery Subject pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AMG 386</keyword>
	<keyword>AMG 706</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Peptibody</keyword>
	<keyword>Sunitinib</keyword>
</DOC>